Angiotensin receptor blockers and microalbuminuria in hypertensive patients with early (microalbuminuric) stage diabetic nephropathy

Molecular Medicine Reports

Volumn 1, Issue 3, 2008, Pages 391-393

  Arai, Tadashi ^a   Ohashi, Hiroshige ^b  

^a Arai Clinic   (Japan)

^b GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

Author keywords

Angiotensin receptor blocker; Microalbuminuria; Renal protection; Telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; LOSARTAN; TELMISARTAN; VALSARTAN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; COMORBIDITY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; RENAL PROTECTION;

EID: 69249137880     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.1.3.391     Document Type: Article

References (10)

1. Hillege HL, Fidler V, Diercks GF, van Gilst WH, De Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee D and De Jong PE for the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group: Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106: 1777-1782, 2002.
2. Parving HH, Lewis JB, Ravid M, Remuzzi G and Hunsicker LG for the DEMAND investigators: Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 69: 2057-2063, 2006.
3. Agrawal B, Berger A, Wolf K and Luft FC: Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 14: 223-228, 1996. (Pubitemid 26121865)
4. Gaede P, Tarnow L, Vedel P, Parving HH and Pedersen O: Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 19: 2784-2788, 2004. (Pubitemid 39480973)
5. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z and Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001. (Pubitemid 34940825)
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R and Raz I; Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001. (Pubitemid 34940824)
7. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J and Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952-1961, 2004.
8. Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M and Katayama S: The telmisartan renoprotective study from incipient nephropathy to overt nephropathy - rationale, study design, treatment plan and baseline characteristics of the incipient to overt: angiotensin II receptor blocker, telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study. J Int Med Res 33: 677-686, 2005. (Pubitemid 43009595)
9. Wienen W, Hauel N, Van Meel JC, Narr B, Ries U and Entzeroth M: Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 110: 245-252, 1993. (Pubitemid 23257787)
10. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA and Kurtz TW: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43: 993-1002, 2004. (Pubitemid 38579904)